People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Clovis Oncology, Inc. | — | Pharmaceuticals | Series D+ | $358.3M | $6.8B | 2013 |
| IntegenX Inc | — | Biotechnology | Series C | $133.9M | $2.0B | 2011 |
| Zogenix Inc | — | Pharmaceuticals | Series C | $131.2M | $526.4M | 2009 |
| aTYR PHARMA INC | — | Biotechnology | Series C | $122.1M | $1.9B | 2015 |
| Axial Biotherapeutics, Inc. | — | Pharmaceuticals | Series B | $109.8M | $107.8M | 2016 |
| ChromaCode, Inc. | — | Biotechnology | Series B | $94.2M | $21.4M | 2017 |
| Applied Proteomics, Inc. | — | Biotechnology | Series B | $50.4M | $1.1B | 2011 |
| Gene Sciences, Inc. | — | Other Health Care | Series A | $8.0M | $161.4M | 2016 |
James C. Blair at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James C. Blair on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.